| |
|
|
|
|
|
|
|||
|
Blood, 18 June 2009, Vol. 113, No. 25, pp. 6411-6418. Prepublished online as a Blood First Edition Paper on February 11, 2009; DOI 10.1182/blood-2008-07-170589.
MYELOID NEOPLASIA MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT11 Department of Medicine, 2 Comprehensive Cancer Center, 3 Molecular Virology, Immunology and Medical Genetics, 4 College of Pharmacy, and 5 Department of Veterinary Biosciences, Ohio State University, Columbus; 6 Section of Molecular Hematology and Therapy, Department of Blood and Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston; and 7 Department of Molecular & Cellular Biochemistry, Ohio State University, Columbus
Aberrant DNA hypermethylation contributes to myeloid leukemogenesis by silencing structurally normal genes involved in hematopoiesis. MicroRNAs (miRNAs) are noncoding RNAs that regulate gene expression by targeting protein-coding mRNAs. Recently, miRNAs have been shown to play a role as both targets and effectors in gene hypermethylation and silencing in malignant cells. In the current study, we showed that enforced expression of miR-29b in acute myeloid leukemia cells resulted in marked reduction of the expression of DNA methyltransferases DNMT1, DNMT3A, and DNMT3B at both RNA and protein levels. This in turn led to decrease in global DNA methylation and reexpression of p15INK4b and ESR1 via promoter DNA hypomethylation. Although down-regulation of DNMT3A and DNMT3B was the result of a direct interaction of miR-29b with the 3' untranslated regions of these genes, no predicted miR-29b interaction sites were found in the DNMT1 3' untranslated regions. Further experiments revealed that miR-29b down-regulates DNMT1 indirectly by targeting Sp1, a transactivator of the DNMT1 gene. Altogether, these data provide novel functional links between miRNAs and aberrant DNA hypermethylation in acute myeloid leukemia and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||